Digestive tract tumors are malignant diseases characterized by high aggressiveness, heterogeneity and metabolic abnormalities. Heterogeneity and drug resistance among tumors pose a serious challenge to targeted therapies. Recent in-depth studies on metabolic reprogramming and immune imbalance in tumor cells have revealed new avenues for therapeutic interventions and emphasized that metabolic and immune imbalance is one of the important hallmarks of cancer. Metabolic reprogramming in gastrointestinal tumors mainly involves energy metabolism, fatty acid metabolism, bone metabolism, and the metabolism of specific amino acids (e.g., arginine, glutamine), which are critical for tumor growth and drug resistance. In addition, recent studies have found that in tumor patients, the body's immune system is being tightly linked to metabolic reprogramming in an unprecedented way, which will lead to new areas of oncology research. However, the exact link between metabolic reprogramming and immune imbalance in cancer is not fully understood.
Currently, we are in the era of precision medicine. With the rapid development of multi-omics and single-cell sequencing, this will help to further elucidate the role of metabolic reprogramming in tumors and provide a broader vision for the development of novel metabolically targeted drugs. At the same time, a major challenge lies in how to translate the complexity of metabolic reprogramming into actionable therapeutic targets, taking into account the dynamic changes in the immune homeostasis of tumor cells. In the near future, the development of personalized therapies targeting metabolic reprogramming and immune imbalance will provide new perspectives to improve patient prognosis.
This research topic aims to provide a comprehensive research article and review, explore the role of metabolic reprogramming and immune imbalance in tumor progression using multi omics, and develop personalized targeted therapies for metabolic processes. We invite researchers working in the following areas to contribute:
1. Combine multi-omics and single cells to reveal the link between metabolic reprogramming and tumor immune imbalance.
2. To develop novel drugs, inhibitors and new therapeutics targeting metabolic processes in gastrointestinal cancer.
3. Combine multi-omics and machine learning to investigate the key role of metabolic reprogramming in tumor progression.
4. Explore the paradigm of combining metabolically targeted drugs with immunosuppressive agents for anti-tumor therapy.
5. Reveal the role of metabolic reprogramming in personalized treatment of gastrointestinal tumors.
6. Integrate spatial transcriptomics and single-cell sequencing to identify different umor subtypes based on metabolic reprogramming.
7. Explore the role of metabolic reprogramming and immune imbalance in gastrointestinal tumor progression.
Digestive tract tumors are malignant diseases characterized by high aggressiveness, heterogeneity and metabolic abnormalities. Heterogeneity and drug resistance among tumors pose a serious challenge to targeted therapies. Recent in-depth studies on metabolic reprogramming and immune imbalance in tumor cells have revealed new avenues for therapeutic interventions and emphasized that metabolic and immune imbalance is one of the important hallmarks of cancer. Metabolic reprogramming in gastrointestinal tumors mainly involves energy metabolism, fatty acid metabolism, bone metabolism, and the metabolism of specific amino acids (e.g., arginine, glutamine), which are critical for tumor growth and drug resistance. In addition, recent studies have found that in tumor patients, the body's immune system is being tightly linked to metabolic reprogramming in an unprecedented way, which will lead to new areas of oncology research. However, the exact link between metabolic reprogramming and immune imbalance in cancer is not fully understood.
Currently, we are in the era of precision medicine. With the rapid development of multi-omics and single-cell sequencing, this will help to further elucidate the role of metabolic reprogramming in tumors and provide a broader vision for the development of novel metabolically targeted drugs. At the same time, a major challenge lies in how to translate the complexity of metabolic reprogramming into actionable therapeutic targets, taking into account the dynamic changes in the immune homeostasis of tumor cells. In the near future, the development of personalized therapies targeting metabolic reprogramming and immune imbalance will provide new perspectives to improve patient prognosis.
This research topic aims to provide a comprehensive research article and review, explore the role of metabolic reprogramming and immune imbalance in tumor progression using multi omics, and develop personalized targeted therapies for metabolic processes. We invite researchers working in the following areas to contribute:
1. Combine multi-omics and single cells to reveal the link between metabolic reprogramming and tumor immune imbalance.
2. To develop novel drugs, inhibitors and new therapeutics targeting metabolic processes in gastrointestinal cancer.
3. Combine multi-omics and machine learning to investigate the key role of metabolic reprogramming in tumor progression.
4. Explore the paradigm of combining metabolically targeted drugs with immunosuppressive agents for anti-tumor therapy.
5. Reveal the role of metabolic reprogramming in personalized treatment of gastrointestinal tumors.
6. Integrate spatial transcriptomics and single-cell sequencing to identify different umor subtypes based on metabolic reprogramming.
7. Explore the role of metabolic reprogramming and immune imbalance in gastrointestinal tumor progression.